On May 1, 2020 OrigiMed (Shanghai), a precision medicine company, reported a collaboration with Germany’s Bayer to develop a China in vitro companion diagnostic (CDx-IVD) to detect NTRK gene fusions (Press release, ChinaBio, MAY 1, 2020, View Source [SID1234556913]). Bayer’s larotrectinib (Vitrakvi) is a TRK inhibitor approved in the US (2018) and EU (2019) to treat adult and pediatric patients with solid tumor TRK fusion cancers. Larotrectinib is being developed globally, including in China. OrigiMed uses high-throughput analysis together with bioinformatics and clinical data to match patients with targeted therapies, immunotherapies and clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!